Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on Esketamine intranasal spray and covered by US commercial health plans.
Kruti JoshiDominic PilonAditi ShahChristopher HolidaySwapna KarkareMaryia ZhdanavaPublished in: Journal of medical economics (2023)
The majority of patients completed ESK induction phase, and most dosing intervals were longer than the label recommendation. In this descriptive analysis, mental health-related inpatient and ED costs trended lower post-ESK initiation.
Keyphrases
- healthcare
- mental health
- end stage renal disease
- ejection fraction
- public health
- emergency department
- newly diagnosed
- peritoneal dialysis
- palliative care
- prognostic factors
- depressive symptoms
- cross sectional
- risk assessment
- patient reported outcomes
- health insurance
- climate change
- human health
- sleep quality
- health promotion
- patient reported